Figure 1.

Timeline of animal studies and groups. (A) Doxorubicin cardiotoxicity animal study in C57BL6 mice with or without ET administration. Mice (except for saline controls) were given 6 mg/kg doxorubicin weekly for 3 weeks and monitored periodically for a further 5 weeks. (B) A breast cancer model using injection of 4T1 cells into the mammary fat pad of BALB-C mice was used to evaluate the direct effect of ET on tumor growth and doxorubicin chemotherapy. Animals administered with doxorubicin were given 6 mg/kg doxorubicin weekly for 3 weeks. In both studies, animals supplemented with ET were given 70 mg/kg ET daily for 7 days prior to the commencement of the study, then once weekly thereafter until the completion of the study.